Chemical scaffolds, structure-activity relationships, and therapeutic potential of EphA2 small-molecule inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase frequently overexpressed in various malignant tumors.
• EphA2 signaling pathways regulate critical cancer processes including proliferation, migration, invasion, and angiogenesis.
• Its overexpression makes EphA2 a promising target for developing novel anticancer therapeutics.

Purpose of the Study:

• To provide a comprehensive review of small-molecule EphA2 inhibitors.
• To systematically summarize chemical scaffolds, structure-activity relationships, binding modes, and pharmacological profiles of EphA2 inhibitors.
• To highlight challenges and offer guidance for designing next-generation EphA2-targeted drugs.

Main Methods:

• Literature review of published research on EphA2 inhibitors.
• Systematic summarization of chemical scaffolds and their properties.
• Analysis of structure-activity relationships and binding modes.
• Evaluation of pharmacological profiles and clinical translation challenges.

Main Results:

• Numerous small-molecule inhibitors targeting EphA2 have been developed across diverse chemical scaffolds.
• Detailed structure-activity relationships and binding interactions have been elucidated for various inhibitors.
• Pharmacological profiles and potential therapeutic applications are discussed.
• Key challenges including selectivity, pharmacokinetics, and clinical translation are identified.

Conclusions:

• Small-molecule inhibitors targeting EphA2 represent a significant area of anticancer drug discovery.
• Understanding SAR, binding modes, and pharmacological profiles is crucial for optimization.
• Addressing challenges in selectivity, pharmacokinetics, and clinical translation is essential for therapeutic success.